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Abstract
For the 28 member states of the European Union, Regulation (EU) No 536/2014 on 
clinical trials on medicinal products for human use, which repeals Directive 2001/20/EC, 
represents a substantial innovation in the procedures for authorising clinical trials and for 
handling all the subsequent stages. It introduces a single authorisation that will be valid 
for all EU member states, as well as a single portal through which all data concerning all 
clinical trials performed throughout the EU will pass. The present article offers an over-
view of the general aspects of the new procedures. It does not address the specific issues 
involved, each of which merits separate examination.
IntroduCtIon
Regulation (EU) No 536/2014 of the European 
Parliament and of the Council of 16th April 2014 on 
clinical trials on medicinal products for human use, 
and repealing Directive 2001/20/EC [1], establishes 
a new set of harmonised rules that all member states 
are required to apply in all clinical trials performed 
throughout the European Union (EU). 
The Regulation is long and detailed (99 articles, di-
vided into 19 chapters, plus 7 annexes) and, as it is 
a Regulation rather than a Directive, is immediately 
applicable and binding in all member states, without 
the need for it to be transposed into the legislation 
of individual states. Regulations are thus of particular 
importance.
The Regulation aims, among other things: to ensure 
that the procedures for authorisation are efficient and 
rapid; to simplify specific sponsor obligations; to guar-
antee public access to information regarding clinical 
trials. To this end the European Medicines Agency 
(EMA) will cooperate with member states to set up 
and maintain a portal and database at Union level.
The present article describes those parts of the Reg-
ulation that, in general, affect the path of a request for 
authorisation, from submission to assessment and the 
final decision. Given the complexity of the procedure, 
it offers an overview of the Regulation and does not 
discuss specific sections that concern such issues as: 
notification of the start, conclusion or temporary halt 
of a clinical trial and of the end of the recruitment 
of subjects; substantial modifications to the protocol; 
the labelling of investigational medicinal products and 
auxiliary medicinal products; safety reporting (adverse 
events and unexpected serious adverse reactions); the 
protection of specific categories of subjects; compen-
sation for damages; supervision by member states, in-
spections and controls at EU level; specific rules for 
specific circumstances, such as cluster trials or clinical 
trials in emergency situations.
overvIew
The need for a review of the regulatory framework 
for clinical trials was widely recognised in view of the 
problems raised by Directive 2001/20/EC [2], particu-
larly in regard to: differences in implementation levels 
across member states; the excessive levels of bureau-
cracy involved in meeting the administrative require-
ments of the Directive, some of which were not effec-
tively justified; the need for multiple applications for 
trials involving more than one state; difficulties in han-
dling divergent decisions, especially in relation to the 
opinions expressed by ethics committees; the lengthy 
and uncertain time intervals required for authorisa-
tions; the shortcomings of the Directive with regard to 
the increasingly global scale of clinical trials [3, 4]. The 
debate on how to move beyond the Directive involved 
numerous parties [5] and lasted several years [6] be-
fore culminating in the adoption of the Regulation.
The Regulation entered into force on 16th June 
2014 but will not be applicable until six months after 
the EU portal and database have become fully func-
tional, and in any case not before 28th May 2016. 
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An interim period of three years is envisaged, dur-
ing which trials for which a request for authorisa-
tion was submitted before the entry into force of the 
Regulation will continue to be governed by Directive 
2001/20/EC. A period in which the two systems will 
overlap is also envisaged, with the effect that submis-
sions under the current system will be valid until at 
least 28th May 2016.
In agreement with principles widely shared through-
out the world [7] and stated in earlier documents 
concerning clinical trials [8], one of the key general 
principles established in the Regulation is that a clini-
cal trial may be performed only if “the rights, safety, 
dignity and well-being of subjects” are protected and 
the data generated are “reliable and robust”. In addi-
tion, the “interests of the subjects should always take 
priority over all other interests”.
SCoPe And defInItIonS
The Regulation applies to all clinical trials conduct-
ed within the EU. A long list of definitions (Article 
2) distinguishes between “clinical studies” and “clini-
cal trials”. Because the two definitions are particularly 
important to understanding the scope of the Regula-
tion, it is worthwhile quoting them in full:
• “Clinical study means any investigation in relation to 
humans intended: a) to discover or verify the clinical, 
pharmacological or other pharmacodynamic effects of 
one or more medicinal products; b) to identify any 
adverse reactions to one or more medicinal products; 
or c) to study the absorption, distribution, metabo-
lism and excretion of one or more medicinal products; 
with the objective of ascertaining the safety and/or ef-
ficacy of those medicinal products”.
• “Clinical trial means a clinical study which fulfils any 
of the following conditions: a) the assignment of the 
subject to a particular therapeutic strategy is decided 
in advance and does not fall within normal clinical 
practice of the Member State concerned; b) the deci-
sion to prescribe the investigational medicinal prod-
ucts is taken together with the decision to include 
the subject in the clinical study; or c) diagnostic or 
monitoring procedures in addition to normal clinical 
practice are applied to the subjects”.
Thus only interventional studies are “clinical trials” 
and fall within the scope of the Regulation: the Reg-
ulation does not apply either to non-interventional 
studies or to medical devices (unless they are part of a 
clinical trial involving a medicinal product). 
The Regulation also defines new concepts absent 
from the earlier rules. 
These include: 
- Low-intervention clinical trials: these are trials that 
use authorised (rather than investigational) medicinal 
products and that do not pose a substantial additional 
risk compared with clinical practice. The procedures 
for these categories of trial are simpler and involve 
fewer obligations regarding monitoring, traceability 
and insurance;
- Co-sponsor. The sponsor, a figure already present 
in the earlier regulations, is the health centre (or per-
son) responsible for a clinical trial. Because the or-
ganisation of trials frequently entails the intervention 
of several organisations rather than a single party, the 
Regulation envisages the possibility of “co-sponsors” 
who share the same responsibilities unless a different 
arrangement is set out in a written contract;
- Auxiliary medicinal products. These are products 
included in the protocol of a clinical trial but not as 
investigational products.
One particularly important issue addressed is the 
public disclosure of clinical trial data. The EU data-
base will contain a summary of the results of trials as 
well as a summary for laypersons, which the sponsor 
is required to submit within a year of the conclusion 
of the trial (regardless of the outcome): the clinical 
study report must be submitted within 30 days of ob-
taining marketing authorisation or withdrawing the 
application. All the information on the EU database 
will be accessible to the public, with the exception of: 
personal data; confidential commercial information 
(unless there is an overriding public interest in disclo-
sure); confidential communications between Member 
States relating to the assessment report; information 
whose disclosure would jeopardise effective supervi-
sion of the conduct of a trial by Member States.
 
AuthorISAtIon ProCedure 
for ClInICAl trIAlS
The Regulation prescribes a precise and detailed 
procedure for the submission, assessment and evalua-
tion of requests for authorisation of clinical trials.
This section briefly examines the key stages of this 
procedure.
The Regulation requires that the application dossier 
for clinical trials comprises two parts.
Part I –  which deals mainly with the type of clinical 
trial, risk-benefit analysis, compliance with technical 
requirements – is assessed by the so-called “report-
ing member state” chosen by the sponsor of the trial 
from the 28 EU member states. The Part I assessment 
submitted by the reporting member state is valid for 
the entire EU. According to the regulations in force 
prior to approval of Regulation 536, specific authori-
sation for multi-centre trials to be conducted in dif-
ferent states had to be obtained in each participating 
state. For trials performed in all 28 member states it 
was thus necessary to submit 28 dossiers to as many 
regulatory authorities and to apply for 28 authorisa-
tions. Regulation 536 provides instead for a single ap-
plication and a single authorisation, and is expected 
to simplify and streamline considerably the process of 
obtaining authorisation.
Part II deals with intrinsically national aspects, 
such as informed consent and the compensation of 
subjects, which are assessed by each state separately 
in a procedure that also involves ethical committees.
As the procedures for assessment and decision-
making are different for Parts I and II it is worthwhile 
examining them separately.
Part I
The sponsor proposes a reporting member state, 
which performs the assessment in cooperation with 
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the other member states concerned. The proposed re-
porting member state may refuse to be the reporting 
member state, or another member state may propose 
to be the reporting member state within three days of 
submission of the application dossier.
Annex I of the Regulation lists the items that must 
be contained in Part I of the dossier (common to all 
the member states concerned), including, among oth-
ers: introduction (covering, where appropriate, previ-
ous applications, co-sponsors, etc.); cover letter; ap-
plication form; clinical trial protocol; investigator’s 
brochure; documentation relating to compliance with 
Good Manufacturing Practice (GMP); Investiga-
tional Medicinal Product Dossier (IMPD); Auxiliary 
Medicinal Product Dossier; copy or summary of any 
scientific advice of the European Medicines Agency 
and Paediatric Investigation Plan (PIP), where appro-
priate; content of the labelling of the investigational 
medicinal products; proof that data will be processed 
in compliance with Union law on data protection.
The Regulation states that “it should be left to 
member states to establish the language requirements 
for the application dossier”, but the recommendation 
that “a commonly understood language in the medi-
cal field” be used seems an implicit suggestion that 
English is the preferred language. The possibility of 
submitting applications in languages other than Eng-
lish will have to be tested in practice.
Applicants may refer to data generated by another 
clinical trial only if the other trial was conducted either 
in compliance with the Regulation or, in the event it 
was performed prior to full application of the Regula-
tion, in compliance with Directive 2001/20/EC.
If the clinical trial referred to was conducted out-
side the Union, it must have been conducted “in ac-
cordance with principles equivalent to those of the 
Regulation as regards the rights and safety of the 
subject and the reliability and robustness of the data 
generated”. Data generated in clinical trials initiated 
prior to full application of the Regulation are to be 
submitted in an application dossier only if the trial 
was registered prior to its start in a public register that 
is a primary or partner registry of, or data provider to, 
the World Health Organisation (WHO) International 
Clinical Trials Registry Platform (ICTRP), or if its re-
sults were published in an independent peer-reviewed 
scientific publication. 
The Regulation establishes brief and precise timelines.
Applications are to be validated within 10 days 
of their submission by the sponsor, and the report-
ing member states (for Part I of the dossier) and the 
member states concerned (for Part II of the dossier) 
must submit an assessment report within 45 days of 
the validation date. As already noted, only one valida-
tion of Part I – which is valid throughout the EU –  is 
required for each trial.
In the event that supplementary information is re-
quired, a single extension period is granted, totalling 
not more than 15 days (10 days for the sponsor to 
respond and 5 days for the decision by the reporting 
member state).
An additional extension of 50 days is possible for 
clinical trials that involve particular types of medicinal 
products, specifically advanced therapy investigation-
al medicinal products.
A system of tacit approval is established in the event 
a member state does not respond within the period 
specified.
Parts I and II may be submitted together, or Part 
I may be submitted in advance for review and agree-
ment before the submission of Part II. In addition, 
if the sponsor so requests, ”the application for au-
thorisation of a clinical trial, its assessment and the 
conclusion shall be limited to the aspects covered by 
Part I of the assessment report”. Following notifica-
tion of the conclusion regarding the aspects covered 
in Part I, the sponsor may, within two years, apply for 
“an authorisation limited to aspects covered by Part 
II of the assessment report”, in which case he must 
declare “that he is not aware of any new substantial 
scientific information that would change the validity 
of any item submitted in the application” regarding 
aspects covered by Part I. If Parts I and II are submit-
ted separately, Part II may not be presented before 
the assessment of Part I has been completed.
The separate submission of Part I before that of 
Part II could be useful in cases involving particularly 
complex protocols whose design and acceptability 
need to be agreed before additional details can be de-
fined to take account of local peculiarities.
During the initial assessment of Part I, the report-
ing member state prepares a draft assessment report 
that is circulated among the member states con-
cerned for their consideration and comments. The 
reporting member state then sends the final scientific 
assessment report to the sponsor within 45 days of 
validation of the submission. During this period the 
reporting member state (but not the member states 
concerned) may ask the sponsor for additional infor-
mation, in which case the deadline for the response is 
extended by 31 days (for a total of 76 days), made up 
as follows: 12 days for the sponsor to reply; 12 days 
for a coordinated review, 7 days for the reporting 
member state to finalise the assessment report, which 
will declare that the trial is: acceptable; acceptable 
subject to conditions; or not acceptable. The dead-
lines are calculated on the basis of calendar days, not 
working days.
Part II
Part II contains country-specific information: re-
cruitment arrangements; subject information; in-
formed consent form and informed consent proce-
dure; suitability of the investigator; suitability of the 
facilities; proof of insurance cover or indemnification; 
financial and other arrangements; proof of payment 
of the fee.
Part II is assessed separately in each member state 
concerned and covers: informed consent; rewards or 
compensations; arrangements for recruitment; com-
pliance with Directive 95/46 (data protection) [9]; 
suitability of the sponsor or of the Contract Research 
Organisation (CRO) to conduct the clinical trial; ad-
equacy of the insurance;  compliance with provisions 
Carlo Petrini
O
r
ig
in
a
l
 a
r
t
ic
l
e
s
 a
n
d
 r
e
v
ie
w
s
320
on the collection, storage and use of biological materi-
al. These aspects are examined by ethics committees.
If Parts I and II are submitted together, the dead-
line for notification of the final decision on Part II is 
the same as that for Part I, i.e. 45 days after valida-
tion of the submission. Each member state may, “with 
justified reasons”, asks the sponsor for additional in-
formation, limited to the aspects covered in Part II. 
In this case the deadline for the decision may be ex-
tended by 31 days (12 of which are for the sponsor 
to reply and 19 for the member state to finalise the 
decision). If the assessment of Part I takes up the full 
period of 76 days the decision must be given within 
five days thereafter.
If a member state concerned fails to communicate 
its decision within 5 days of the reporting date of the 
assessment of Part I or of the end of the assessment of 
Part II (whichever is later), the decision given in the 
final assessment of the reporting member state shall 
be deemed to be valid.
A member state that does not accept the decision 
on Part I of the assessment report shall not participate 
in the trial.
A member state may reject the decision on Part I in 
the following circumstances:
• if it considers that participation in the clinical trial 
would lead to a subject receiving treatment inferior to 
that which he or she would receive in normal clinical 
practice in the member state concerned;
• if the clinical trial involves a violation of specific “na-
tional law prohibiting or restricting the use of any spe-
cific type of human or animal cells, or the sale, supply 
or use of medicinal products containing, consisting of 
or derived from those cells, or of medicinal products 
used as abortifacients or of medicinal products con-
taining narcotic substances within the meaning of the 
relevant international conventions in force”;
• on grounds of considerations regarding data reliabil-
ity and robustness raised by the member state con-
cerned during the assessment of Part I.
GenerAl CommentS
The Regulation introduces procedures with very 
precise timelines. The requirement of a single sub-
mission and a single approval for Part I that are valid 
throughout the EU will considerably simplify the au-
thorisation process.
Some of the operational aspects regarding the sub-
mission, assessment and decision still have to be de-
fined, presumably when the Regulation  becomes fully 
applicable. 
On the basis of the above, it is worth indicating the 
following:
• The designation of a single reporting member state 
whose assessment and decision are valid throughout 
all 28 EU member states could, for various reasons, 
lead to sponsors giving preference to some states over 
others. It is therefore to be expected that a limited 
number of states will act as reporting member state 
for the majority of trials.
• Compliance with the deadlines indicated in the 
Regulation will involve a considerable effort and may 
cause a number of operational problems both for the 
competent authorities and for ethics committees.
• Coordination between competent authorities and 
ethics committees will need to be carefully estab-
lished, particularly when Parts I and II are presented 
together and the two assessments are processed in 
parallel within the same national timetable.
• The Regulation does not fully clarify some of the 
operational aspects concerning the role of ethics com-
mittees in assessing Part II. Specifically, it is not clear 
whether the issue of an opinion by an ethics commit-
tee is part of Part II: the data sent through the EU 
portal do not appear to include approval of ethical as-
pects, although those relating to Part II, which specif-
ically concerns ethical aspects, are included. Nor does 
the Regulation clarify whether approval is required by 
each local ethics committee or only at national level. 
It is probable that local ethics committees will consid-
er issues affecting local sites and that a single decision 
on the trial will apply per country.
• The requirement that data concerning trials and a 
summary of the results be made accessible to the pub-
lic, including laypersons, is in agreement with a widely 
practised approach [10]; a similar position is included 
in the most recent revision of the Declaration of Hel-
sinki [11], which includes two articles devoted spe-
cifically to “Research Registration and Publication and 
Dissemination of Results”. Article 35 states that: “Every 
research study involving human subjects must be regis-
tered in a publicly accessible database before recruit-
ment of the first subject”. Article 36 states that: “Re-
searchers, authors, sponsors, editors and publishers all 
have ethical obligations with regard to the publication 
and dissemination of the results of research. Research-
ers have a duty to make publicly available the results of 
their research on human subjects and are accountable 
for the completeness and accuracy of their reports. All 
parties should adhere to accepted guidelines for ethical 
reporting. Negative and inconclusive as well as positive 
results must be published or otherwise made publicly 
available. Sources of funding, institutional affiliations 
and conflicts of interest must be declared in the pub-
lication (...)”. The EMA has on several occasions been 
urged to review its policies on the publication of and 
access to clinical trial data [12] and is looking into the 
issue [13].  However, not all the rules for access to data 
have yet been wholly clarified. It would be reasonable, 
for instance, to ensure the confidentiality of trial results 
until marketing authorisation is granted.
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